Article, originally posted on News-Medical.net
A group from The Mount Sinai Hospital / Mount Sinai School of Medicine have identified and characterized a novel potassium-channel activator, GiGA1, capable of selectively opening a subset of potassium channels to produce an antiseizure effect in animal models.
This study presents an integrated approach to GIRK1-specific activators, employing both computational modeling and subsequent biochemical and physiological studies. The resultant seizure mitigation produced in an acute epilepsy mouse model demonstrates a potential role for this compound in the treatment of brain disorders.